Aptar Pharma’s Latest Webinar “Growing Confidence in Airless Dispensing”
On March 14, people from around the world participated in Aptar Pharma’s live webinar “Growing Confidence in Airless Dispensing”.
Aptar Pharma experts, Dr. Stefan Hellbardt and Thomas Hauser, led the webinar, and outlined in detail the principles and benefits of airless dispensing solutions over traditional packaging. Aptar Pharma also presented their comprehensive product, service and support package, which underscores their trusted partner status for modern drug packaging development projects.
Polls conducted throughout the webinar helped to confirm the need to educate packaging and pharmaceutical industry professionals about airless dispensing systems technology. At the end of the hour-long educational webinar, attendees rated the quality of the webinar as “valuable”.
In addition, more than 50 percent of poll respondents agreed that the key benefits of airless dispensing for them were the protection of their drug formulation and the increase of end-user convenience. The large number of questions raised at the end of the webinar confirmed the considerable interest in modern packaging solutions such as airless dispensing in the pharmaceutical industry today.
Aptar Pharma’s airless dispensing solutions have launched with various drug formulations and have the power to be the first packaging solution of choice in the future for viscous pharmaceutical formulations.
Aptar Pharma’s Preservative-Free Multidose Dispenser Chosen for the First Time for a Prescription Dry Eye Product in the US with RESTASIS MULTIDOSE™
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is available for patients in the U.S. prescription market for the first time with Allergan’s RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%.
This approval and launch makes the Aptar Pharma Ophthalmic Squeeze Dispenser the very first, and only, U.S. FDA-approved multidose delivery system to handle prescription eye treatment formulations without any preservatives.
Meeting the needs of patients
Aptar Pharma is working closely with eye care specialist Allergan to improve patient safety, achieve dosing accuracy and maintain product integrity.
Dry eye patients use eye drops on a regular basis, and often for the rest of their lives. It is well-proven that preserved medications may cause unpleasant and sometimes serious side effects.
The increasing number of patients experiencing eye irritation or allergic reactions with preserved formulations appreciate the fact that preservatives can be removed from eye care medications with Aptar Pharma’s Ophthalmic Squeeze Dispenser system. RESTASIS® and RESTASIS MULTIDOSE™ are FDA-approved prescription treatments to help patients suffering from Chronic Dry Eye to make more of their own tears.
Making ophthalmic solutions easier and safer to deliver
Aptar Pharma’s Ophthalmic Squeeze Dispenser system is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions. Patients and consumers in Europe, Latin America and Asia have benefited from this technology since 2012 with more than 100 commercial references now available on the market.
RESTASIS® is not an artificial tear. It is a prescription medicine that helps increase the eyes’ natural ability to produce tears.
“Our Ophthalmic Squeeze Dispenser technology has been a great success for our customers,” explained Salim Haffar, President, Aptar Pharma. “The proven and unrivalled microbiological safety, combined with a precise and reproducible drop ejection allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the FDA.” Mr. Haffar also points out the user-friendliness of the system, “The ergonomic and pocket-size design and the intuitiveness of a squeezable container with a low actuation force certainly contribute to the high levels of acceptance among patients and consumers around the world.”
Staying ahead of the market
Aptar Pharma’s Ophthalmic Squeeze Dispenser provides a unique competitive advantage by addressing the global trend towards patient-friendly, cost-effective and preservative-free multidose dispensers.
Aptar Pharma Inaugurates Congers Site Expansion
Aptar Pharma’s site expansion in Congers, NY was inaugurated on March 20th by Stephan Tanda, AptarGroup’s President and CEO, Salim Haffar, President of Aptar Pharma, and Alex Theodorakis, President Aptar Pharma North America. Several Aptar Pharma customers in North America were invited to attend this inaugural event.
Aptar Pharma’s newly-expanded, state-of-the-art manufacturing capabilities will be used to complete premium injectable elastomeric component manufacturing, enabling Aptar Pharma to better serve its North American pharmaceutical customers.
“The new expansion supports growth in three directions,” explained Bas van Buijtenen, President, Injectables Division, Aptar Pharma. “It adds capacity to our network of global manufacturing sites and will be equipped with the latest technologies to meet growing quality requirements. The proximity to our North American customer base improves our service and responsiveness.”
Following this event, Aptar Pharma will welcome current and future customers and partners during the Drug, Chemical & Associated Technologies Association (DCAT) Week and Interphex, at booth 1734.
Aptar Pharma’s Electronic Lockout Device Approved by EMA
Aptar Pharma, a world leader in innovative drug delivery systems, is pleased to announce the approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG. Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl®. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuardTM.
This represents a major milestone for Aptar Pharma, with the e-Lockout device being the first and only fully integrated electronic nasal drug delivery device to be approved by a U.S. or European regulatory authority.
Already available in unidose and multidose nasal spray versions, Takeda will launch Instanyl® DoseGuard in Europe in several multidose strengths, all using Aptar Pharma’s patented electronic lockout system, which marks another product innovation in the management of breakthrough pain.
Advanced e-Device Technology Ensures Safe Compliance
Instanyl® is a fast-acting nasal opioid approved for relieving breakthrough pain in adult cancer patients already treated with opioids for their usual pain. Breakthrough pain is an additional sudden pain that occurs despite having taken one’s usual pain relieving medicines.
Aptar Phama’s e-Lockout device uses advanced electronic technology to help patient compliance in the treatment of chronic disease. Aptar Pharma’s e-Lockout device is intended to ensure safe patient compliance by limiting the number of doses available during a 24 hour period.
The system’s built-in lock-out mechanism prevents the device from being used for a period of time after a pre-defined number of spray actuations. The electronic display shows the number of priming strokes, the number of doses left in the device and whether the nasal spray is locked or ready for use. The e-Lockout also features a child-resistant cap.
Long-term Strategic Partnership with Takeda
The multi-year supply agreement reinforces a long-standing partnership between Takeda and Aptar Pharma, who currently supplies Takeda with unidose and multidose nasal spray devices for Instanyl® in Europe.
Committed to accompanying pharmaceutical companies throughout their product lifecycle management, Aptar Pharma continues to partner to provide customers with innovative and smart solutions to enable safe, convenient and compliant medication delivery.
“This approval and subsequent product launch underscores Aptar Pharma’s ability to partner with the pharma industry to bring innovative, compliant and safer devices through the regulatory authorization process,” explained Salim Haffar, President, Aptar Pharma. “This is yet another example of Aptar Pharma’s expertise and technology at the heart of a new market launch. This is a significant step in strengthening Aptar Pharma’s credentials in the electronics and connected health markets. We are pleased to be building on our trusted, long-term partnership with Takeda,” he added.